α-syn

α-syn aggregation inhibitor-1 (Compound 2e) acts as an inhibitor of α-syn aggregation. It is capable of inhibiting the cell viability of SH-SY5Y.

tau Protein α-synuclein-IN-2 (Compound 14T) is a tau and α-synuclein inhibitor capable of crossing the blood-brain barrier. It reduces α-synuclein oligomerization in a dose-dependent manner through a thiourea linker structure. In biosensor cells, tau Protein α-synuclein-IN-2 prevents tau aggregation seed effects. In the M17D neuroblastoma model, this compound exhibits anti-inclusion effects and reduces Aβ plaque formation. tau Protein α-synuclein-IN-2 shows potential for Alzheimer's and Parkinson's disease research.

α-Synuclein inhibitor 3 (Compound 7g) is a potent inhibitor of α-synuclein (α-Syn) aggregation, with potential applications in Parkinson's disease research [1].

α-Synuclein inhibitor 6 (compound 3ge) is a blood-brain barrier-permeable agent that effectively inhibits α-Synuclein (α-Syn) aggregation, demonstrating a potent IC50 value of 1.70 μM and achieving an inhibition ratio of 94.4% at 30 μM [1].

α- Synuclein inhibitor 7 (compound 3gf) is effective α- Synuclein ( α- Syn) aggregation inhibitor, IC50 is 1.95 μM, inhibition rate at 30μM was 85.8%. α- Synuclein inhibitor 7 has blood-brain barrier permeability.

α-Synuclein inhibitor 5 is a potent inhibitor of α-Synuclein (α-Syn) aggregation across the blood-brain barrier (IC50: 1.22 μM), with 94.3% inhibition at 30 μM.

α-Synuclein inhibitor 9 (Compound 20C) targets and binds to cavities within mature α-synuclein fibrils, diminishing their β-sheet content. It effectively inhibits the aggregation of A53T α-synuclein, exhibits neuroprotective properties, enhances brain functionality, and alleviates motor impairments. This compound is utilized in research related to Parkinson's disease (PD). [1]

Tau protein α-synuclein-IN-1 is a dual inhibitor that not only impedes tau protein and α-synuclein but also reduces the development of α-syn inclusions in M17D neuroblastoma cells, making it a useful agent in the study of Alzheimer's disease [1].

α-Synucleinmodulator 1 (Compound 7k) acts as a modulator of α-synuclein. In an ACN PBS (1:1) buffer solution, it exhibits maximum absorption and emission wavelengths at 386 nm and 603 nm, respectively.

α-Synuclein (61-75) is a peptide fragment derived from the larger protein α-Synuclein, which is predominantly found in presynaptic nerve terminals and considered a biomarker candidate for Parkinson's disease (PD).

α-Synuclein inhibitor 4 (compound 3gh) is a highly effective, blood-brain barrier-permeable inhibitor of α-Synuclein aggregation, demonstrating potent activity with an IC50 value of 0.98 μM and an inhibition ratio of 91.2% at 30 μM [1].

Dyrk1A α-synuclein-IN-1 (Compound b1) is a dual inhibitor of Dyrk1A (IC50: 177 nM) and α-synuclein aggregation (IC50: 10.5 μM), characterized by CNS permeability and neuroprotective activity.

Dyrk1A α-synuclein-IN-2 (Compound b20) is a dual inhibitor of Dyrk1A and α-synuclein aggregation with an IC50 of 7.8 μM for α-synuclein. It exhibits high predictive CNS permeability and has a neuroprotective effect.

α-Synuclein inhibitor 8 effectively impedes α-Synuclein aggregation and disaggregation with an IC50 of 2.5 µM, demonstrating substantial reduction in neuronal inclusion formation, which contributes to reparative effects in damaged neurons and symptomatic improvement in Parkinson's disease (PD)-like models. The compound also exhibits high antioxidant activity and low cytotoxicity [1].

α-Synuclein (61-75) TFA is a fragment (residues 61-75) of the predominantly presynaptic neuronal protein α-Synuclein, serving as a potential biomarker for Parkinson's disease (PD) [1] [2].

PROTAC α-synuclein degrader 3 (compound 5) is a potent and selective agent for degrading α-synuclein, used in Parkinson's disease research [1].

PROTAC α-synuclein degrader 5 is a highly selective (PROTAC) compound targeting and degrading α-synuclein aggregates, with a DC50 value of 7.51 μM and a maximum degradation rate (Dmax) of 89%. It incorporates the probe molecule sery308 and E3 ligase ligands, suitable for neurological disease research [1].

α-Synuclein (61-95) (human) constitutes the hydrophobic core of α-synuclein and is implicated in inducing neuronal cell death. This segment is utilized in the study of neurodegenerative conditions such as Alzheimer's disease (AD) and Parkinson's disease (PD) [1] [2].

α-Synuclein 4554W, previously identified through intracellular library screening, is an inhibitor of α-Synuclein (aSyn) aggregation and its associated toxicity. This compound, comprising GIVNGVKA sequences, effectively reduces fibril formation in aSyn mutants associated with Parkinson's disease [1].

α-Synuclein (67-78) (human), a fragment spanning amino acids 67 to 78 of α-Synuclein, enhances network activity drive and inhibits the uptake of syt1L-ab induced by KCl [1].

alphaSYN-IN-NAB2, a neuron-protective agent, is a protein encoded by the NAB2 gene. NAB2 effectively and selectively protects a variety of cells from alpha-SYN toxicity. NAB2 promotes endosomal transport dependent on E3 ubiquitin ligase Rsp5 Nedd4. NAB2 identifies a viable molecular node in alpha-SYN biology that corrects multiple aspects of its underlying pathology, including dysfunctional endosomes and endoplasmic reticulum to Golgi vesicles transport. NAB2 is involved in cellular processes such as cell differentiation, apoptosis and stress response, and can be used to study cancer, neurodevelopment and neuronal activity.

Tolcapone (Ro 40-7592) is a catechol-O-methyltransferase inhibitor employed as an adjunctive therapy with levodopa and carbidopa in the treatment of Parkinson's disease.

Entacapone sodium salt inhibits catechol-O-methyltransferase(COMT) with similar IC50 in different tissues including live, duodenum, kidney and lung, but entacapone is more active than tolcapone in those tissues. Entacapone (< 100 μM) is a potent inhibitor of α-syn and β-amyloid (Aβ) oligomerization and fibrillogenesis, and also protects against extracellular toxicity induced by the aggregation of both proteins in PC12 cells.Entacapone sodium salt is a specific, potent, peripherally acting catechol-O-methyltransferase (COMT) inhibitor with IC50 of 151 nM for PD treatment.